Posterior cingulate γ-aminobutyric acid and glutamate/glutamine are reduced in amnestic mild cognitive impairment and are unrelated to amyloid deposition and apolipoprotein E genotype
Open accessThe DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Abstract
The biomarker potential of the inhibitory neurotransmitter γ-aminobutyric acid (GABA) for the in vivo characterization of preclinical stages in Alzheimer’s disease has not yet been explored. We measured GABA, glutamate + glutamine (Glx), and N-acetyl-aspartate (NAA) levels by single-voxel MEGA-PRESS magnetic resonance spectroscopy in the posterior cingulate cortex of 21 elderly subjects and 15 patients with amnestic mild cognitive impairment. Participants underwent Pittsburgh Compound B positron emission tomography, apolipoprotein E (APOE) genotyping, and neuropsychological examination. GABA, Glx, and NAA levels were significantly lower in patients. NAA was lower in Pittsburgh Compound B-positive subjects and APOE ε4 allele carriers. GABA, Glx, and NAA levels were positively correlated to CERAD word learning scores. Reductions in GABA, Glx, and NAA levels may serve as metabolic biomarkers for cognitive impairment in amnestic mild cognitive impairment. Because GABA and Glx do not seem to reflect amyloid β deposition or APOE genotype, they are less likely biomarker candidates for preclinical Alzheimer’s disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Winblad, B., Palmer, K., Kivipelto, M., Jelic, V., Fratiglioni, L., Wahlund, L. ‐., Nordberg, A., Bäckman, L., Albert, M., Almkvist, O., et al. (2004) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2004.01380.x · Cited by 4,946
Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS–ADRDA criteria
Dubois, B., Feldman, H. H., Jacova, C., DeKosky, S. T., Barberger-Gateau, P., Cummings, J., Delacourte, A., Galasko, D., Gauthier, S., Jicha, G., et al. (2007) · The Lancet Neurology · doi:10.1016/s1474-4422(07)70178-3 · Cited by 4,411
Moms, J. C., Heyman, A., Mohs, R. C., Hughes, J. P., van Belle, G., Fillenbaum, G., Mellits, E. D., & Clark, C. (1989) · Neurology · doi:10.1212/wnl.39.9.1159 · Cited by 4,130
Restriction isotyping of human apolipoprotein E by gene amplification and cleavage with HhaI.
Hixson, J., & Vernier, D. (1990) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)43176-1 · Cited by 2,933
Revising the definition of Alzheimer's disease: a new lexicon
Dubois, B., Feldman, H. H., Jacova, C., Cummings, J. L., DeKosky, S. T., Barberger-Gateau, P., Delacourte, A., Frisoni, G., Fox, N. C., Galasko, D., et al. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(10)70223-4 · Cited by 1,869 · cited 1×
“Introduction Current diagnostic criteria for research define preclinical and prodromal stages of Alzheimer’s disease (AD) based on biomarkers (Albert et al., 2011; Dubois et al., 2007, 2010; Sperling et al., 2011).”
Alzheimer Mechanisms and Therapeutic Strategies
Huang, Y., & Mucke, L. (2012) · Cell · doi:10.1016/j.cell.2012.02.040 · Cited by 1,758 · cited 1×
“Moreover, the most important genetic risk factor for late-onset AD, apolipoprotein E genotype (APOE), may exert at least part of its effect through impairment of GABAergic interneurons (Huang and Mucke, 2012).”
Sperling, R. A., LaViolette, P. S., O'Keefe, K., O'Brien, J., Rentz, D. M., Pihlajamaki, M., Marshall, G., Hyman, B. T., Selkoe, D. J., Hedden, T., et al. (2009) · Neuron · doi:10.1016/j.neuron.2009.07.003 · Cited by 1,027 · cited 2×
“Beyond MRS, functional MRI appears to be sensitive to Aβ deposition, because aberrant default network activity (Sperling et al., 2009) and decreased functional connectivity (Sheline et al.”
Sheline, Y. I., Raichle, M. E., Snyder, A. Z., Morris, J. C., Head, D., Wang, S., & Mintun, M. A. (2010) · Biological Psychiatry · doi:10.1016/j.biopsych.2009.08.024 · Cited by 597
Chen, Y., Durakoglugil, M. S., Xian, X., & Herz, J. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0914984107 · Cited by 368
Andrews-Zwilling, Y., Bien-Ly, N., Xu, Q., Li, G., Bernardo, A., Yoon, S. Y., Zwilling, D., Yan, T. X., Chen, L., & Huang, Y. (2010) · The Journal of Neuroscience · doi:10.1523/jneurosci.4040-10.2010 · Cited by 326
Wolk, D. A., Dickerson, B. C., Initiative, T. A. D. N., Weiner, M., Aiello, M., Aisen, P., Albert, M. S., Alexander, G., Anderson, H. S., Anderson, K., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1001412107 · Cited by 248
Lanctôt, K. L., Herrmann, N., Mazzotta, P., Khan, L. R., & Ingber, N. (2004) · The Canadian Journal of Psychiatry · doi:10.1177/070674370404900705 · Cited by 191 · cited 1×
“However, the preclinical and pathologic evidence for alterations in GABAergic neurotransmission in AD is conflicting (Lanctôt et al., 2004).”
Reduced hippocampal glutamate in Alzheimer disease
Rupsingh, R., Borrie, M., Smith, M., Wells, J. L., & Bartha, R. (2011) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2009.05.002 · Cited by 177 · cited 18×
“None of the subjects changed in cognitive status (i.e., HCS to aMCI or aMCI to AD; or vice versa) in the time period between study inclusion, MRS examination, and neuropsychological testing.”
InfluentialModrego, P. J., Fayed, N., & Pina, M. A. (2005) · American Journal of Psychiatry · doi:10.1176/appi.ajp.162.4.667 · Cited by 135 · cited 2×
“Furthermore, MRS was found to improve prognostic accuracy for conversion from MCI to dementia (Modrego et al., 2005) and even from cognitive health to MCI (Kantarci et al.”
Brain Glutamate Levels Are Decreased in Alzheimer’s Disease: A Magnetic Resonance Spectroscopy Study
Fayed, N., Modrego, P. J., Rojas-Salinas, G., & Aguilar, K. (2011) · American Journal of Alzheimer's Disease & Other Dementias® · doi:10.1177/1533317511421780 · Cited by 128 · cited 4×
“Indeed, in the only other study investigating GABA levels in aMCI and HCS, treatment with growth hormone-releasing hormone increased GABA levels and improved cognitive function (Friedman et al., 2013).”
InfluentialDecreased glutamate + glutamine in Alzheimer’s disease detected in vivo with 1 H-MRS at 0.5 T
Antuono, P. G., Jones, J. L., Wang, Y., & Li, S.-J. (2001) · Neurology · doi:10.1212/wnl.56.6.737 · Cited by 119
APOE genotype affects the pre‐synaptic compartment of glutamatergic nerve terminals
Dumanis, S. B., DiBattista, A. M., Miessau, M., Moussa, C. E. H., & Rebeck, G. W. (2013) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2012.07908.x · Cited by 55 · cited 2×
“Similar to our findings, total tissue GABA and Glu content (as determined by MRS) did not differ between 1-year-old ApoE-e4 TR and ApoE-e3 TR mice (Dumanis et al., 2013).”
Cited by
Song, T., Song, X., Zhu, C., Patrick, R., Skurla, M., Santangelo, I., Green, M., Harper, D., Ren, B., Forester, B. P., et al. (2021) · Ageing Research Reviews · doi:10.1016/j.arr.2021.101503 · Cited by 346
Bi, D., Wen, L., Wu, Z., & Shen, Y. (2020) · Alzheimer's & Dementia · doi:10.1002/alz.12088 · Cited by 232
Jiménez-Balado, J., & Eich, T. S. (2021) · Seminars in Cell & Developmental Biology · doi:10.1016/j.semcdb.2021.01.005 · Cited by 183
Alzheimer’s disease: Targeting the glutamatergic system
Conway, M. E. (2020) · Biogerontology · doi:10.1007/s10522-020-09860-4 · Cited by 180
APOE and Alzheimer’s Disease: Neuroimaging of Metabolic and Cerebrovascular Dysfunction
Brandon, J. A., Farmer, B. C., Williams, H. C., & Johnson, L. A. (2018) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2018.00180 · Cited by 75
Metadata
- Authors
- Riese, F., Gietl, A., Zölch, N., Henning, A., O’Gorman, R., Kälin, A. M., Leh, S. E., Buck, A., Warnock, G., Edden, R. A. E., Luechinger, R., Hock, C., Kollias, S., & Michels, L.
- Venue
- Neurobiology of Aging
- Publisher
- Elsevier BV
- Published
- 2015-01
- Volume
- 36
- Issue
- 1
- Pages
- 53-59
- ISSN
- 0197-4580 (ISSN-L)
- OpenAlex
- W2078096700
- Cited by
- 80
- References
- 17
- FWCI
- 3.82
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.